BMC Medical Genomics (Nov 2019)

Return of genetic and genomic research findings: experience of a pediatric biorepository

  • Tanya Papaz,
  • Eriskay Liston,
  • Laura Zahavich,
  • Dimitri J. Stavropoulos,
  • Rebekah K. Jobling,
  • Raymond H. Kim,
  • Miriam Reuter,
  • Anastasia Miron,
  • Erwin Oechslin,
  • Tapas Mondal,
  • Lynn Bergin,
  • John F. Smythe,
  • Luis Altamirano-Diaz,
  • Jane Lougheed,
  • Roderick Yao,
  • Oyediran Akinrinade,
  • Jeroen Breckpot,
  • Seema Mital

DOI
https://doi.org/10.1186/s12920-019-0618-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Assess process, uptake, validity and resource needs for return of actionable research findings to biobank participants. Methods Participants were prospectively enrolled in a multicenter biorepository of childhood onset heart disease. Clinically actionable research findings were reviewed by a Return of Research Results Committee (RRR) and returned to the physician or disclosed directly to the participant through a research genetic counselor. Action taken following receipt of this information was reviewed. Results Genetic data was generated in 1963 of 7408 participants. Fifty-nine new findings were presented to the RRR committee; 20 (34%) were deemed reportable. Twelve were returned to the physician, of which 7 were disclosed to participants (median time to disclosure, 192 days). Seven findings were returned to the research genetic counselor; all have been disclosed (median time to disclosure, 19 days). Twelve families (86%) opted for referral to clinical genetics after disclosure of findings; 7 results have been validated, 5 results are pending. Average cost of return and disclosure per reportable finding incurred by the research program was $750 when utilizing a research genetic counselor; clinical costs associated with return were not included. Conclusions Return of actionable research findings was faster if disclosed directly to the participant by a research genetic counselor. There was a high acceptability amongst participants for receiving the findings, for referral to clinical genetics, and for clinical validation of research findings, with all referred cases being clinically confirmed.

Keywords